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Introduction: A major subset of patients with rheumatoid arthritis (RA) is characterized by the presence of
circulating autoantibodies directed to citrullinated proteins/peptides (ACPAs). These autoantibodies, which are
commonly detected by using an enzyme-linked immunosorbent assay (ELISA) based on synthetic cyclic citrullinated
peptides (CCPs), predict clinical onset and a destructive disease course. In the present study, we have used plasma
and synovial fluids from patients with RA, for the affinity purification and characterization of anti-CCP2 reactive
antibodies, with an aim to generate molecular tools that can be used in vitro and in vivo for future investigations
into the pathobiology of the ACPA response. Specifically, this study aims to demonstrate that the surrogate marker
CCP2 can capture ACPAs that bind to autoantigens expressed in vivo in the major inflammatory lesions of RA
(that is, in the rheumatoid joint).
Methods: Plasma (n = 16) and synovial fluid (n = 26) samples were collected from RA patients with anti-CCP2 IgG
levels of above 300 AU/mL. Total IgG was isolated on Protein G columns and subsequently applied to CCP2 affinity
columns. Purified anti-CCP2 IgG was analyzed for reactivity and specificity by using the CCPlus® ELISA, in-house
peptide ELISAs, Western blot, and immunohisto-/immunocytochemistry.
Results: Approximately 2% of the total IgG pool in both plasma and synovial fluid was CCP2-reactive. Purified
anti-CCP2 reactive antibodies from different patients showed differences in binding to CCP2 and differences in
binding to citrullinated peptides from α-enolase, vimentin, fibrinogen, and collagen type II, illustrating different
ACPA fine-specificity profiles. Furthermore, the purified ACPA bound not only in vitro citrullinated proteins but, more
importantly, in vivo-generated epitopes on synovial fluid cells and synovial tissues from patients with RA.
Conclusions: We have isolated ACPAs from plasma and synovial fluid and demonstrated that the CCP2 peptides,
frequently used in diagnostic ELISAs, de facto act as surrogate antigens for at least four different, well-characterized,
largely non-cross-reactive, ACPA fine specificities. Moreover, we have determined the concentration and proportion
of CCP2-reactive IgG molecules in rheumatoid plasma and synovial fluid, and we have shown that the purified
ACPAs can be used to detect both in vitro- and in vivo-generated citrullinated epitopes by various techniques.
We anticipate that these antibodies will provide us with new opportunities to investigate the potential pathogenic
effects of human ACPAs.* Correspondence: karin.lundberg@ki.se
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Autoimmunity in a major subset of patients with rheu-
matoid arthritis (RA) is characterized by the presence
of disease-specific autoantibodies directed against post-
translationally citrullinated proteins/peptides (ACPAs)
[1-3]. These antibodies can be detected years before cli-
nical manifestations of arthritis [4,5], their presence pre-
dicts a more erosive disease course [6], and an enrichment
in the joints compared with the circulation [7] suggests a
local production and a pathogenic involvement. However,
relatively little is known about the potential pathogenic ef-
fects of the human ACPA response. Hence, more in-depth
molecular studies of ACPAs are warranted. To facilitate
such future investigations, we have in the present study
isolated and characterized ACPAs from RA synovial fluid
(SF) and plasma.
Routine testing for ACPAs in clinical practice is com-
monly performed by using a commercial enzyme-linked
immunosorbent assay (ELISA) based on cyclic citrulli-
nated peptides (CCPs), the so-called “second generation”
anti-CCP ELISA [2]. Today, this assay constitutes an im-
portant diagnostic tool for RA and is also widely used in
research studies on ACPAs. However, anti-CCP2 reactive
antibodies target synthetic peptides that do not corres-
pond to any human protein sequence, and thus these
antibodies act as surrogate markers for autoimmunity in
RA without formally defining any reactivity against auto-
antigens present in vivo.
We and others have investigated the fine specificity of
the ACPA response [8-12] and demonstrated reactivity
to citrullinated epitopes on proteins expressed in the
rheumatoid joint, including α-enolase [13,14], fibrinogen
[15], vimentin [16], collagen type II (CII) [17], immuno-
globulin binding protein (BiP) [18], annexin [19], and
histone 4 [20]. The frequencies of ACPAs reactive with
single autoantigen-derived peptides are in most patient
cohorts lower than the frequency of anti-CCP2 reactive
antibodies, whereas the number of RA patients who are
positive for any of these ACPA fine specificities is similar
to the number of anti-CCP2-positive patients (typically
around 60% to 70%) [21]. Notably, reactivity to the
autoantigen-derived citrullinated peptides can also be
detected in a minor subset of anti-CCP2-negative patients.
Peptide-absorption experiments demonstrate limited cross-
reactivity between different ACPA fine specificities, and
different ACPA-reactivity patterns can be seen in different
patients [10-12,21].
Whether the same antibodies that react with the CCP2
peptides used in the diagnostic ELISA also react with
citrullinated antigens expressed in tissues and cells from
rheumatoid joints, including the four most extensively
studied ACPA targets (citrullinated α-enolase, vimentin,
fibrinogen, and collagen type II), has never been for-
mally demonstrated (with the exception of citrullinatedfibrinogen) [22]. A prerequisite for such studies involves
the isolation of human anti-CCP2 reactive antibodies.
Hence, in the present study, where we have affinity-
purified ACPAs on CCP2 columns, we have had the op-
portunity to investigate the reactivity of anti-CCP2 IgG
in detail. We have also been able to determine the con-
centration and proportion of CCP2-reactive IgG mole-
cules in rheumatoid plasma and SF; importantly, we
have demonstrated that the purified ACPAs can be used
as molecular tools for the detection of in vitro- and
in vivo-generated citrullinated epitopes by ELISA, Western
blot, and immunohisto-/immunocytochemistry.Materials and methods
Patients
Non-paired synovial fluid (n = 26) and plasma (n = 16)
samples were collected with informed consent from RA
patients attending the rheumatology clinic at Karolinska
University Hospital, Stockholm, Sweden, from 2001 to
2011. Synovial fluid was collected from patients requiring
arthrocentesis. All patients fulfilled the American College
of Rheumatology/European League Against Rheumatism
criteria for RA [23-25] and were selected on the basis of
having high anti-CCP2 antibody levels (>300 AU/mL).
Samples were stored at −20°C (short term) or −80°C (long
term) until processed. The study was approved by the re-
gional ethics committee at Karolinska Institutet.Affinity purification of human anti-CCP2 IgG
Synovial fluid (10 to 20 mL per sample) was centrifuged
at 4,000 rpm before supernatants were treated with
hyaluronidase (Sigma-Aldrich, St. Louis, MO, USA) for
1 hour at 4°C in order to decrease viscosity. Proteins
were precipitated by using saturated ammonium sul-
phate in accordance with standard protocol [26], dis-
solved in phosphate-buffered saline (PBS), and further
dialyzed against PBS. Plasma (15 to 25 mL per sample)
was centrifuged and diluted 1:5 (vol/vol) in PBS. IgGs
from plasma and SF were purified on HiTrap Protein G
HP columns (GE Healthcare, Stockholm, Sweden) in ac-
cordance with the instructions of the manufacturer.
Eluted IgG fractions were dialyzed against PBS and fil-
tered before being applied to the CCP2 affinity column,
kindly provided by Euro-Diagnostica AB (Malmö,
Sweden). The CCP2 column was subsequently washed
with 10 column volumes of PBS before bound anti-
CCP2 IgG was eluted by using 0.1 M glycine-HCl buffer
(pH 2.7) and directly neutralized with 1 M Tris (pH 9)
(Figure 1). Buffer exchange to PBS and concentration of
antibodies was performed in one step, applying the 10-
kDa Microsep™ UF Centrifugal Device (Pall Life Science,
Port Washington, NY, USA) in accordance with the in-
structions of the manufacturer.
Figure 1 Anti-CCP2 IgG was efficiently purified from plasma and synovial fluid. Schematic illustration of the anti-CCP2 IgG purification
process. (A) Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by Coomassie staining of different protein fractions
collected during the anti-CCP2 IgG purification process is shown. Representative samples from plasma (B) and synovial fluid (C): molecular marker
(lane 1); plasma/precipitated synovial fluid proteins (lane 2); protein G column flow through (lane 3); protein G column IgG eluate, before dialysis
and filtration (lane 4); protein G column IgG eluate, after dialysis and filtration (lane 5); CCP2 column IgG flow through (lane 6); CCP2 column
anti-CCP2 IgG eluate (lane 7). Lanes 2 and 3: 15 μg/well. Lanes 4 to 7: 5 μg/well. IgG, immunoglobulin G; PBS, phosphate-buffered saline.
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CCP2 peptides (2 mg) (corresponding to the patent-
protected peptides used in the commercially available
Immunoscan CCPlus® assay from Euro-Diagnostica AB)
were coupled to 1 mL HiTrap columns (GE Healthcare).
Recommended flow rate and backpressure specifications
were followed (flow rate: 1 mL/min, maximum back-
pressure: 0.3 MPa). Performance of the columns was
typically around 1 mg anti-CCP2 IgG/column.Calculations of total IgG and anti-CCP2 IgG concentrations
in plasma and SF
Protein concentrations were determined in Protein G
column eluate fractions (before and after dialysis and
filtration) and in CCP2 column flow-through and eluate
fractions by using the Bradford DC assay (Bio-Rad
Laboratories, Hercules, CA, USA) and the Nanodrop
Spectrophotometer (Thermo Scientific, Waltham, MA,
USA) in parallel in accordance with the instructions of
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milliliter) of total IgG was calculated on the basis of the
initial plasma or SF volume applied to the Protein G
column and the amount of IgG eluted from the Protein
G column (that is, before dialysis and filtration). The
proportion (percentage) of anti-CCP2 IgG (of total IgG)
was calculated on the basis of the amount of IgG applied
to the CCP2 column (that is, after dialysis and filtration)
and the amount of anti-CCP2 IgG eluted from the CCP2
column. The concentration (in milligrams per milliliter)
of anti-CCP2 IgG was then calculated on the basis of
this proportion (percentage) in relation to the con-
centration (in milligrams per milliliter) of total IgG in
plasma and SF.
SDS-PAGE
Recovery and purity of total IgG and anti-CCP2 IgG were
analyzed by Coomassie brilliant blue staining after protein
separation on sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE). In brief, samples were di-
luted in lithium dodecyl sulphate (LDS) sample buffer
(Invitrogen, Carlsbad, CA, USA) containing dithiothreitol
(DTT) and subjected to denaturation and reduction at
70°C for 10 minutes. Plasma, precipitated SF proteins,
Protein G column flow-through fractions (at 15 μg/well),
Protein G column eluate fractions (before and after dia-
lysis and filtration), and CCP2 column flow-through and
eluate fractions (at 5 μg/well) were loaded onto NuPAGE®
Bis-Tris 4%-12% gels (Invitrogen) and run in 2-(N-morpho-
lino)ethanesulfonic acid (MES)-SDS antioxidant-containing
running buffer at 200 V (constant) for 45 minutes. Protein
bands were visualized by Coomassie brilliant blue staining
(0.2% Comassie blue, 7.5% glacial acetic acid, 50% metha-
nol) in accordance with standard protocol.
ELISAs
Anti-CCP2 reactivity was determined in 10 plasma and
11 SF samples and in the corresponding fractions col-
lected during the anti-CCP2 IgG purification process (as
described above). Samples were analyzed in duplicates
and in serial dilutions (7 × 1:3 dilution steps) starting at
1:100 (plasma and SF) or at 10 μg/mL (fractions) by
using the Immunoscan CCPlus® assay (Euro-Diagnostica
AB) in accordance with the instructions of the manufac-
turer. Cutoff for positivity was 25 AU/mL. Reactivities to
citrullinated peptides from α-enolase (CEP-1; amino acid
5-21), vimentin (Cit-vim; amino acid 60-75), fibrinogen
(Cit-fib; amino acid 36-52), and collagen type II (Cit-C1;
amino acid 359-369) were assayed in the same samples
at the same dilutions by using in-house ELISAs as pre-
viously described [21]. Cutoff for positivity was cal-
culated on the basis of the 98th percentile among 150
healthy controls and set to 10 AU/mL for all ACPA fine
specificities.Western blot
Purified human fibrinogen (Merck, Darmstadt, Germany)
depleted of immunoglobulins, recombinant human α-
enolase, and recombinant mutated human vimentin were
citrullinated in vitro by using rabbit skeletal muscle pepti-
dylarginine deiminase 2 (PAD2) (Sigma-Aldrich) as previ-
ously described [27]. Citrullinated and uncitrullinated
proteins (1 μg/well) were separated on NuPAGE® Bis-Tris
10% gels (Bio-Rad Laboratories), stained with Coomassie
brilliant blue, or transferred to nitrocellulose membranes.
Membranes were blocked with 5% milk, tris-buffered saline
(TBS)/0.05% Tween, probed with a pool of 11 purified anti-
CCP2 IgG eluate fractions from SF, or the corresponding
CCP2 column flow-through IgG pool, at 2 μg/mL, for
1 hour at room temperature (RT), before being washed in
PBS/0.05% Tween and incubated with horseradish pero-
xidase (HRP)-conjugated goat anti-human IgG (The
Jackson Laboratory, Bar Harbor, ME, USA), diluted
1:20,000, for 1 hour at RT. After a final wash, membranes
were subjected to enhanced chemiluminescence (ECL)
development.
Immunohisto-/immunocytochemistry
Synovial hip or knee biopsy specimens were obtained from
three patients with RA by joint replacement surgery and
were snap-frozen in dry ice-cool isopentane; serial cryostat
sections (7 μm) were fixed with 2% (vol/vol) formaldehyde
and stored at −80°C before being stained. Fresh SF mono-
nuclear cells from three patients with RA were prepared by
ficoll separation and fixed in 2% formaldehyde before being
stained. The presence of citrullinated epitopes was detected
by using a pool of 26 purified anti-CCP2 IgG eluate frac-
tions from SF and the corresponding flow-through IgG
pool. The antibody pools were biotinylated (Light-
ning-Link™ Biotin conjugation kit; Innova Biosciences,
Cambridge, UK) and used at 10 μg/mL for staining synovial
tissue or at 5 μg/mL for staining SF cells. PBS/saponine was
used to permeabilize the cells. The vectastain detection sys-
tem (ABC-elite kit, Vector Laboratories, Burlingame, CA,
USA) was used for the tissue, and Streptavidin/HRP (Dako-
Cytomation, Glostrup, Denmark) was used for the cells.
Statistical analyses
Differences in antibody levels (in arbitrary units per
milliliter) between different ACPA fine specificities in
plasma and SF and in the purified anti-CCP IgG2 eluate
fractions were examined by using Mann-Whitney U test
for independent groups.
Results
Efficient purification of anti-CCP2 IgG on CCP2 affinity
columns
Anti-CCP2 IgG was efficiently purified from 16 plasma
and 26 SF samples by using Protein G and CCP2 affinity
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purification process were analyzed by Coomassie stain-
ing after separation on SDS-PAGE (Figure 1B and C).
IgG isolation on the protein G column was confirmed to
efficiently remove non-IgG materials. No degradation,
and only minor loss of protein content (<6%), was ob-
served during the dialysis and filtration step (data not
shown). The CCP2 affinity columns demonstrated high
capacity regarding the amount of target-protein loaded,
and no destructive processes were detected during the
elution, yielding pure and intact anti-CCP2 IgG with
high recovery. The multiple bands around the molecular
weight of the IgG heavy and light chains, seen mainly in
the CCP2 eluate fractions from both plasma and SF,
may represent different isoforms and modifications (for
example, glycosylation [28]) of the IgG molecules.
Concentration and proportion of anti-CCP2 IgG in plasma
and synovial fluid
By measuring the protein concentration at every step of
the purification process, we have calculated the concen-
tration of anti-CCP2 IgG in the circulation and locally in
the joint (Table 1). The concentration of anti-CCP2 IgG
was higher in plasma (median value of 0.2 mg/mL) than
in SF (median value of 0.06 mg/mL), but since the
concentration of total IgG was also higher in plasma
(median value of 14.6 mg/mL) compared with SF (median
value of 3.5 mg/mL), in line with what has previously been
described [29,30], the proportion of IgG molecules with
CCP2 reactivity was in fact marginally higher in SF
(median value of 2.2%, with four samples above 6%) than
in plasma (median value of 1.5% and a highest recorded
proportion of 3.6%).
Anti-CCP2 IgG contain ACPA of various fine specificities
Anti-CCP2 reactivity was monitored throughout the pu-
rification process by using the Immunoscan CCPlus®
ELISA. No anti-CCP2 IgG response could be detected in
any of the Protein G or CCP2 column flow-through frac-
tions, whereas strong CCP2 reactivity was recorded in
all Protein G column eluate fractions and in all CCP2
column eluate fractions (data not shown). The purified
anti-CCP2 IgG eluate fractions as well as the cor-
responding flow-through fractions from 10 plasma andTable 1 Concentrations and proportion of anti-CCP2 IgG in p
Plasma (n
Median
Total IgG concentration, mg/mL 14.6
Anti-CCP IgG concentration, mg/mL 0.2
Proportion of anti-CCP IgG, %a 1.5
aCalculated as the percentage of anti-CCP2 IgG of total IgG. CCP, cyclic citrullinated11 SF samples were further tested (by ELISA) in serial
dilutions for reactivity with CCP2 as well as four well-
characterized ACPA epitopes on citrullinated α-enolase
(CEP-1), vimentin (Cit-vim), fibrinogen (Cit-fib), and
collagen type II (Cit-C1). Differences in binding capacity
to CCP2 were observed between anti-CCP2 IgG purified
from different patients, as demonstrated by marked dif-
ferences in absorption (that is, AU/mL values) between
samples, despite being analyzed at the same antibody
concentration (Figure 2). A large majority of CCP2
column eluate fractions from both plasma and SF was
positive for all four ACPA fine specificities (Table 2 and
Figure 2), whereas the flow-through fractions were con-
sistently negative (data not shown).
Five plasma samples and 10 SF samples were consid-
ered negative for one or several ACPA fine specificities
on the basis of the cutoff value for positivity of 10 AU/
mL. Still, purified anti-CCP2 IgGs from these samples
were considered positive (that is, above the cutoff value
for positivity) (Table 2). The reason for this discrepancy
is most likely due to differences in ACPA concentrations
between the purified anti-CCP2 IgG eluates, which were
tested at 10 μg/mL, and the original “pre” plasma and SF
samples, which were tested at a lower concentration
(that is, a dilution of 1:100).
No correlations could be observed between strong
CCP2-binding and presence of specific ACPA fine-
specificity patterns. In fact, several anti-CCP2 IgG eluates
with weak binding to CCP2 seemed to have particularly
strong binding to CEP-1 (Figure 2). Moreover, purified
anti-CCP2 IgG from SF showed significantly stronger re-
activity with CEP-1 compared with the other citrullinated
peptides (P <0.01). Median reactivities were 447 AU/mL
for anti-CEP-1 and 40, 97, and 62 AU/mL for anti-Cit-
vim, anti-Cit-fib, and anti-Cit-C1, respectively (Table 2).
This observation was mirrored by significantly higher
anti-CEP-1 IgG levels in the original “pre” SF samples
compared with the other ACPA fine specificities. This
anti-CEP-1 “enrichment” was specific for SF and could
not be seen in plasma/anti-CCP2 IgG purified from
plasma.
Reactivity of the purified ACPA was further analyzed
by Western blot, in which a pool of 11 purified anti-
CCP2 IgG eluate fractions from SF bound in vitro-lasma and synovial fluid





peptide; IgG, immunoglobulin G; SF, synovial fluid.
Figure 2 (See legend on next page.)
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Figure 2 Anti-CCP2 IgG contains autoantibodies directed to citrullinated proteins/peptides (ACPAs) of various fine specificities. Analysis
was conducted by enzyme-linked immunosorbent assay (ELISA). ACPA responses in purified anti-CCP2 IgG eluates were measured by ELISA in 10
plasma samples (left panel) and 11 synovial fluid samples (right panel). Anti-CCP2 IgG response (top panel), anti-CEP-1 IgG response, anti-Cit-vim
IgG response, anti-Cit-fib IgG response, and anti-Cit-C1 IgG response (bottom panel) are shown. X-axis shows anti-CCP2 IgG eluate concentrations
(μg/mL). Y-axis shows ACPA levels (AU/mL). Anti-CCP2 IgG eluates highlighted in red indicate samples with particularly weak binding to the CCP2
ELISA plates. CCP, cyclic citrullinated peptide; CEP-1, citrullinated α-enolase peptide 1 (amino acid 5-21); Cit-C1, citrullinated triple helical peptide/
epitope on collagen type II (amino acid 359-369); Cit-fib, citrullinated fibrinogen peptide (β-chain, amino acid 36-52); Cit-vim, citrullinated vimentin
peptide (amino acid 60-75); IgG, immunoglobulin G.
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β-chains, α-enolase, and mutated vimentin, whereas
the corresponding CCP2 column flow-through IgG
pool bound neither the citrullinated nor the native pro-
teins (Figure 3).Table 2 ACPA IgG responses (AU/mL) in 10 plasma and 11 sy
column purification
Plasma CCP CEP-1
Pre Post Pre Post
RA 1 >3,200 >3,200 142 254
RA 2 505 >3,200 104 1,207
RA 3 >3,200 >3,200 44 225
RA 4 >3,200 >3,200 97 1,052
RA 5 >3,200 >3,200 24 30
RA 6 >3,200 >3,200 13 43
RA 7 >3,200 >3,200 140 69
RA 8 >3,200 >3,200 11 15
RA 9 763 >3,200 17 135
RA 10 1,151 >3,200 <10 24
Median 3,200 3,200 34 102
Synovial fluid CCP CEP-1
Pre Post Pre Post
RA 11 2,447 >3,200 173 447
RA 12 311 1,780 <10 117
RA 13 596 >3,200 15 1,339
RA 14 1,196 >3,200 22 109
RA 15 508 >3,200 67 183
RA 16 435 >3,200 16 46
RA 17 378 1,311 51 610
RA 18 592 1,282 688 900
RA 19 1,084 >3,200 85 339
RA 20 515 1,537 67 1,271
RA 21 566 897 101 900
Median 566 3,200 67a 447a
“Pre” samples were tested at a dilution of 1:100, and “Post” samples were tested at
Cit-vim, Cit-fib, and Cit-C1). aAnti-CEP-1 IgG levels in synovial fluid were significantly
levels (P <0.01). CCP, cyclic citrullinated peptide; CEP-1, citrullinated α-enolase pept
collagen type II (amino acid 359-369); Cit-fib, citrullinated fibrinogen peptide (β-cha
60-75); IgG, immunoglobulin G; RA, rheumatoid arthritis.Purified anti-CCP2 IgGs bind antigen targets in RA
synovial tissue and SF cells
A pool of 26 purified anti-CCP2 IgG eluate fractions from
SF and the corresponding flow-through IgG pool were
biotinylated and tested for the ability to bind in vivo-novial fluid samples “pre” and “post” CCP2 affinity
Cit-vim Cit-fib Cit-C1
Pre Post Pre Post Pre Post
<10 45 17 417 17 122
<10 101 18 92 <10 20
18 59 101 518 333 333
30 65 33 79 77 195
21 35 104 139 114 172
30 70 18 36 <10 <10
107 348 282 155 170 86
<10 27 42 168 17 26
<10 59 <10 79 73 222
<10 47 <10 92 18 38
9 59 25.5 115.5 45.5 104
Cit-vim Cit-fib Cit-C1
Pre Post Pre Post Pre Post
31 14 28 163 <10 <10
15 131 <10 156 <10 <10
19 32 <10 34 <10 185
<10 <10 <10 152 30 18
<10 191 <10 253 <10 200
<10 40 <10 <10 <10 111
<10 167 <10 97 <10 44
<10 17 <10 17 <10 48
23 115 17 187 19 62
<10 17 <10 21 <10 80
<10 113 <10 80 <10 146
0 40 0 97 0 62
10 μg/mL. Cutoffs for positivity: 25 AU/mL (CCP) and 10 AU/mL (CEP-1,
higher than the other anti-citrullinated protein/peptide antibody (ACPA)
ide 1 (amino acid 5-21); Cit-C1, citrullinated triple helical peptide/epitope on
in, amino acid 36-52); Cit-vim, citrullinated vimentin peptide (amino acid
Figure 3 Anti-CCP2 IgG contains autoantibodies directed to citrullinated proteins/peptides (ACPAs) of various fine specificities. Analysis
was conducted by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot. SDS-PAGE was followed by Coomassie
staining and Western blot of uncitrullinated and citrullinated: fibrinogen, mutated vimentin, and α-enolase (all at 1 μg/well). Coomassie staining (left),
Western blot using a pool of 11 purified anti-CCP2 IgG eluate fractions from synovial fluid (center) or a pool of the corresponding CCP2 column IgG
flow-through fractions (right) are shown. CCP, cyclic citrullinated peptide; IgG, immunoglobulin G.
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munocytochemistry (Figure 4). Infiltrating cells in in-
flamed RA synovial tissue stained positive using the ACPA
IgG pool, whereas staining with the corresponding flow-
through IgG pool was negative. Likewise, RA SF cells
stained positive with the ACPA pool but negative with the
flow-through pool.
Discussion
Using an efficient and robust method to affinity-purify
ACPAs, we were able to determine the concentration
and the proportion of CCP2-reactive IgG molecules in
plasma and SF of patients with RA. Based on the sam-
ples analyzed in our study, approximately 2% of the IgG
pool in both plasma and SF are CCP2-reactive, which
corresponds to anti-CCP2 IgG concentrations of 0.2 and
0.06 mg/mL (median values) in plasma and SF, respec-
tively. These concentrations are somewhat higher than
what was reported in another study [22] but are in line
with what has been described more recently [29] and in
studies of other antigen-specific IgG responses [31,32].
In SF samples from four patients, more than 6% of the
IgG molecules were CCP2-reactive. This high proportion
of ACPA may suggest a local production or enrichment
(or both) of autoantibodies in the inflamed joint, which
also has been proposed in a previous study, in which
higher ACPA levels were detected in SF, compared to
serum, after normalization against total IgG [7]. This ob-
servation is supported by a recent study, in which the
ACPA-specific memory B cells were estimated to consti-
tute as much as 30% of the total memory B-cell pool in
RA SF [33].
Our ELISA data formally demonstrate that the CCP2
peptides commonly used in diagnostic ELISAs de factoact as surrogate antigens for the four most extensively
studied ACPA fine specificities in RA: anti-CEP-1, anti-
Cit-vim, anti-Cit-fib, and anti-Cit-C1 antibodies. The
finding that purified anti-CCP2 IgG identifies citrulli-
nated fibrinogen, α-enolase, and mutated vimentin by
immunoblotting confirms and extends data previously
published by Ioan-Facsinay and colleagues, who could
show that antibodies eluted from CCP2 ELISA plates
bound to citrullinated fibrinogen [22].
The differences seen in binding to CCP2 between the
different anti-CCP2 IgG eluates when analyzed by using
the CCPlus® ELISA suggest that differences in affinity
for the CCP2 peptides exist between patients, which in
turn may depend on the composition of ACPA fine
specificities in the different samples. However, we have
not been able to identify a specific ACPA profile corre-
sponding to strong CCP2 binding. We observed, on the
other hand, that several anti-CCP2 IgG eluates with
weak binding to CCP2 showed particularly strong bin-
ding to CEP-1, which may suggest that anti-CEP-1
antibodies have lower affinity for the CCP2 peptides
compared with the other ACPA fine specificities inves-
tigated here. Still, it is important to note that all anti-
CEP-1 antibodies were captured by the CCP2 column,
as no CEP-1 reactivity was detected in the flow-through
fractions.
In SF and in anti-CCP2 IgG purified from SF, reactivity
with the CEP-1 peptide was significantly stronger than
reactivity with the other citrullinated peptides. These
data are in line with those of a recently published study
by Amara and colleagues, demonstrating that CEP-1 re-
active B-cell clones were more commonly isolated from
RA SF than cit-vim and cit-fib reactive B-cell clones
[33]. The results in both their study and our study may
Figure 4 Purified anti-CCP2 IgGs bind in vivo-generated epitopes in rheumatoid arthritis (RA) synovial tissue and synovial fluid (SF)
cells. Immunohisto-/immunocytochemical stainings of RA synovial tissue (top panel) and RA synovial fluid cells (bottom panel) using a pool of 26
purified anti-CCP2 IgG eluate fractions from SF (left panel) or a pool of the corresponding CCP2 column IgG flow-through fractions (right panel).
Magnifications: 10× (synovial tissue) and 25× (SF cells). Representative pictures from n = 3 RA patients (synovial tissue) and n = 3 RA patients (SF
cells) are shown. CCP, cyclic citrullinated peptide; IgG, immunoglobulin G.
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perform. Still, such differences were not seen in plasma
or in anti-CCP2 IgG purified from plasma. Hence, the
data suggest a specific enrichment or production (or
both) of anti-CEP-1 antibodies in the joint.
Conclusions
Our study demonstrates that anti-CCP2 reactive anti-
bodies constitute at least four different RA-associated
ACPA fine specificities and furthermore that anti-CCP2
IgGs bind in vivo-generated antigens in the rheumatoid
joint. Isolation of human ACPA by using affinity col-
umns with conjugated citrullinated antigens, such as the
CCP2 column described here, or the mutated citrul-
linated vimentin column, previously described by Harre
and colleagues [34], or the more recently describedpurification of ACPA reactive with various citrullinated
CII epitopes, which were shown to bind rheumatoid car-
tilage [35], will allow important functional and structural
in vitro and in vivo studies aimed at elucidating the
mode of action and pathogenic potential of human
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